OmniVison Touts Image Sensor’s Performance in Clinical Study

The Third Eye Retroscope can increase the accuracy in diagnosing adenomas, or pre-cancerous polyps, by 23.2 percent when used in conjunction with a traditional colonoscope.
Author:
Publish date:

OmniVision Technologies, Inc. a developer of advanced digital imaging systems, says its ultra-compact, high-performance OV6930 CMOS image sensor performed well in a recent 448-patient clinical study on Avantis Medical Systems' Third Eye Retroscope.

The study, published in the March issue of Gastrointestinal Endoscopy, demonstrates that the Third Eye Retroscope can increase the accuracy in diagnosing adenomas, or pre-cancerous polyps, by 23.2 percent when used in conjunction with a traditional colonoscope.

Approved by the U.S. Food & Drug Administration (FDA), the Third Eye Retroscope is a disposable, catheter-based camera for use with a standard colonoscope that provides a continuous backward-looking view while the colonoscope provides the usual forward view.

In 2010, Avantis received a Medicare and Medicaid reimbursement code for the Third Eye Retroscope, and the companies believe that recognition by Medicare and Medicaid, combined with the favorable results from this recent clinical study, may significantly accelerate the adoption rate by U.S. health-care providers.

“The OV6930's excellent low-light sensitivity and image quality enabled the Third Eye to perform extraordinarily well in the clinical study, drastically improving colonoscopy accuracy,” said Matthew Whitcombe, OmniVision’s senior marketing manager.

“With currently more than 150,000 cases of colorectal cancer reported annually in the U.S., and more than 400,000 in Europe, it is the second-leading cause of cancer-related deaths in the U.S. and Europe,” said Doug Gielow, Avantis’ vice president of sales and marketing. “However, using today's advanced imaging technologies, it can be highly preventable through early detection,” he added.

Related